![](/img/cover-not-exists.png)
CS3 IRBESARTAN IS PROJECTED TO BE COST AND LIFE SAVING COMPARED TO STANDARD BLOOD PRESSURE CONTROL ALONE FOR TREATMENT OF PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION, AND MICROALBUMINURIA IN SPANISH, SWEDISH AND SWISS SETTINGS
AJ Palmer, S Roze, Valentine Wj, L Annemans, S Gabriel, R ChenVolume:
7
Year:
2004
Language:
english
DOI:
10.1016/s1098-3015(10)65692-6
File:
PDF, 61 KB
english, 2004